4sc Ag

Bayer Intellectual Property Gmbh

Merck Patent Gmbh

Bayer Schering Pharma Ag

Pfizer Corporation

Bayer Pharma Aktiengesellschaft

4sc Discovery Gmbh

Astrid Zimmermann

Volker Gekeler

Thomas Maier

Thomas Beckers

Hemant Joshi

Thomas Bär

Matthias Vennemann

Swen Hölder

Armin Zülch

Sanjeev Anant Kulkarni

Hans-Peter Hofmann

Anil P Jagtap

Ganesh S Chaure

Sarvesh S Patel

Petra Gimmnich

Gerrit Beneke

Umesh Bhise

Siegfried Schneider

Vikas Gore

Sachin Shivatare

Sunil Chavan

Yogesh Munot

Frank Zenke

Beate Schmidt

Christian Sirrenberg

Thomas Baer

Mathias Schmidt

Steffen Weinbrenner

Marat Alimzhanov

Alexander Weber

Uday Joshi

Jürgen Braunger

Florian Dehmel

Thomas Stengel

Heike Dahmen

Martin Falk

Lars Damstrup

Keyvan Tadjalli Mehr

Patricia Soulard

Andreas Schroeder

Mahindra Makhija

Kamlesh Padiya

Thomas Bãr

Lyubomir Vassilev

Thomas Grombacher

Dipak Harel

Sachin S Shivatare

Yogesh S Munot

Sarvesh A Patel

Kamlesh J Padiya

Sanjeev A Kulkarni

Juergen Braunger

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.

Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer

Combination therapy for the treatment of cancer.

Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

Substituted imidazoquinolines

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic imidazoles

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. 

N-sulphonylpyrroles and their use as histone deacetylase inhibitors

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic pyrimidines

Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Indolopyridines as Eg5 kinesin modulators

The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. 

Tetrahydro-fused pyridines as histone deacetylase inhibitors

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1. 

Thiophene-imidazopyridines

Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Growing community of inventors

Constance, Germany

Astrid Zimmermann